IL17A and diabetic kidney disease: As mentioned above, presence of IL-17A in individuals with diabetes and diabetic mouse models is an obvious characteristic, and serum and urinary levels of IL-17A in the former with advanced DKD confirms this finding; additionally, low doses of IL-17A have a noteworthy therapeutic effect on podocytes and tubular cells (44).